We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
BioForce Nanosciences Holdings (PK) | USOTC:BFNH | OTCMarkets | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.08 | 5.63% | 1.50 | 1.33 | 1.65 | 1.50 | 1.33 | 1.39 | 8,100 | 21:00:01 |
1. Name and Address of Reporting Person * KAISER RICHARD KAISER | 2. Issuer Name and Ticker or Trading Symbol BIOFORCE NANOSCIENCES HOLDINGS, INC. [ BFNH ] |
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director __X__ 10% Owner __X__ Officer (give title below) _____ Other (specify below) CFO |
3. Date of Earliest Transaction
(MM/DD/YYYY)
| ||
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person |
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | ||||||||||
1.Title of Security (Instr. 3) | 2. Trans. Date | 2A. Deemed Execution Date, if any |
3. Trans. Code (Instr. 8) |
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) |
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | |||
Code | V | Amount | (A) or (D) | Price | ||||||
Common Stock | 12/4/2020 | A | 3000000 (1) | A | $0.001 | 5050000 | D |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||||||||||
1. Title of Derivate Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | ||||
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||||||
Convertible Preferred 'A' | $0.001 | 12/4/2020 | M (1) | 500000 | 12/31/2020 | 12/31/2040 | Common Stock | 3000000 (1) | $0.001 | 0 | D |
Remarks: This amendment was filed to correct information contained within the footnote #1. The reporting person exchanged 500,000 Preferred 'A' shares for 3,000,000 common shares of the issuer, BioForce Nanosciences Holdings, Inc. The filing corrects the mistake saying reporting person converted 1,500,000 Preferred 'A' shares for 11,000,000 common shares. |
Reporting Owners | |||||
Reporting Owner Name / Address | |||||
Director | 10% Owner | Officer | Other | ||
KAISER RICHARD KAISER 3419 VIRGINIA BEACH BLVD, UNIT 252 VIRGINIA BEACH, VA 23452 | X | X | CFO |
Signatures | ||
/s/ Richard Kaiser | 12/7/2020 | |
**Signature of Reporting Person | Date |
1 Year BioForce Nanosciences (PK) Chart |
1 Month BioForce Nanosciences (PK) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions